Earnings Releases·Nov 3, 2026, 4:09 PM ET

QuidelOrtho — Third Quarter 2026 Earnings Summary

Total revenue declined 12% YoY to $619 million, though underlying growth of 2% was achieved excluding respiratory, China, and U.S. Donor Screening; GAAP net loss widened to $54 million while adjusted EBITDA fell to $148 million.
Full-year 2026 guidance was narrowed across all metrics: revenue to $2.52–$2.54 billion, adjusted EBITDA to $540–$545 million, and adjusted EPS to $0.65–$0.70.
Management initiated a cost transformation and enterprise restructuring program targeting over $80 million in annual savings by 2027, with expected fourth-quarter one-time charges of $30–$35 million.
Segment performance was weighed down by a 38.7% drop in respiratory revenue and a 42.7% decline in China Labs revenue due to pricing changes, while Labs and Immunohematology grew outside China.